DoubleZero has introduced subscription-based order-book data feeds for Hyperliquid's perpetual and spot markets, with prices ranging from $900 to $5,000 per month depending on feed type and location. These feeds use NYSE-style multicast technology to deliver detailed market data, including full Market-by-Order depth, directly from Hyperliquid's validators. The service targets professional market makers and quantitative trading desks seeking faster, more detailed DeFi market data. Pricing is competitive compared to traditional exchanges, making it accessible for institutional crypto traders. This launch marks DoubleZero's third integration on its Edge platform, expanding its institutional DeFi data offerings.
DoubleZero's new paid order-book feeds for Hyperliquid markets come as 43 of 50 major cryptocurrencies on Pluang rose today. For readers following the crypto market, here is Pluang's snapshot as of Sep 25, 2026 00:31 WIB: ALGO gained 8.26% to Rp2.032 with a typical hold time of 129 days and 82% sell order activity; EOS rose 8.13% to Rp12.649 with a hold time of 87 days; and CAKE increased 7.95% to Rp49.548 with 72% sell orders and a 75-day hold time.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
